Bacillus Calmette-Guérin (BCG) vaccine is the live attenuated vaccine form of Mycobacterium bovis used to prevent tuberculosis and other mycobacterial infections. Now, using zebrafish “avatars,” a ...

A Northwestern Medicine study has offered new clues as to why immunotherapy works well for some bladder cancer patients but ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas. Adding subcutaneous sasanlimab to Bacillus ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

Combination significantly improved disease-free survival in phase III trial ...

Patients with early-stage bladder cancer are often able to maintain their usual routines. Some may experience urinary ...

In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

Use of 2 sequential induction courses of BCG for high-risk NMIBC rather than standard induction with maintenance therapy showed an excellent response rate. A novel strategy for using bacillus Calmette ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...